Review




Structured Review

Moderna mrna 3927
Mrna 3927, supplied by Moderna, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna-3927/3927+mrna/pmc13011059-166-0-2
Average 86 stars, based on 1 article reviews
mrna 3927 - by Bioz Stars, 2026-09
86/100 stars

Images

Related Articles

Formulation:

Article Title: Nucleic acid therapeutics: Past, present, and future
Article Snippet: , NCT05130437 , Genetic (propionic acidemia) , LNP , mRNA-3927 (Moderna) , i.v.

Article Title: Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems
Article Snippet: The positive results of mRNA-3927 [ ] developed by Moderna in the clinical trial of treating propionic acidemia reduced the risk of life-threatening metabolic decompensation in patients by 70%, providing new hope for the treatment of rare genetic diseases and further demonstrating the broad prospects of mRNA therapy in the fields of precision medicine and rare disease treatment.

Article Title: Therapeutic applications of cell engineering using mRNA technology.
Article Snippet: Safety advantages are driving the rapid Engineering and reprogramming cells has significant therapeutic potential to treat a wide range of diseases, by replacing missing or defective proteins, to provide transcription factors (TFs) to reprogram cell phenotypes, or to provide enzymes such as RNA-guided Cas9 derivatives for CRISPR-based cell engineering.. While viral vector-mediated gene transfer has played an important role in this field, the use of mRNA avoids safety concerns associated with the integration of DNA into the host cell genome, making mRNA particularly attractive for in vivo applications.. Widespread application of mRNA for cell engineering is limited by its instability in the biological environment and challenges involved in the delivery of mRNA to its target site.

Article Title: Emerging mRNA Technology for Liver Disease Therapy.
Article Snippet: Liver diseases have consistently posed substantial challenges to global health.. It is crucial to find innovative methods to effectively prevent and treat these diseases.. In recent times, there has been an increasing interest in the use of mRNA formulations that accumulate in liver tissue for the treatment of hepatic diseases.

Article Title: Developing mRNA Nanomedicines with Advanced Targeting Functions.
Article Snippet: In 2024, Moderna reported the interim clinical results of mRNA-3927, which was delivered to the liver for the expression of propionyl-coenzyme A carboxylase α or β (PCCA or PCCB) subunits to participate in the conversion of propionic acid (Fig. 11e).

Article Title: Intranasal and Pulmonary Lipid Nanoparticles for Gene Delivery: Turning Challenges into Opportunities
Article Snippet: Beyond respiratory conditions, LNP-mRNA therapeutics are being evaluated for metabolic disorders, including Moderna’s mRNA-3704 for methylmalonic acidemia (Clinical Trial NCT03810690 ) and mRNA-3927 (Clinical Trial NCT04159103 ) for propionic acidemia.

Article Title: Developing mRNA Nanomedicines with Advanced Targeting Functions
Article Snippet: In 2024, Moderna reported the interim clinical results of mRNA-3927, which was delivered to the liver for the expression of propionyl-coenzyme A carboxylase α or β (PCCA or PCCB) subunits to participate in the conversion of propionic acid (Fig. e).

Activity Assay:

Article Title: Nucleic acid therapeutics: Past, present, and future
Article Snippet: , NCT05130437 , Genetic (propionic acidemia) , LNP , mRNA-3927 (Moderna) , i.v.

Article Title: Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems
Article Snippet: The positive results of mRNA-3927 [ ] developed by Moderna in the clinical trial of treating propionic acidemia reduced the risk of life-threatening metabolic decompensation in patients by 70%, providing new hope for the treatment of rare genetic diseases and further demonstrating the broad prospects of mRNA therapy in the fields of precision medicine and rare disease treatment.

Article Title: Therapeutic applications of cell engineering using mRNA technology.
Article Snippet: Safety advantages are driving the rapid Engineering and reprogramming cells has significant therapeutic potential to treat a wide range of diseases, by replacing missing or defective proteins, to provide transcription factors (TFs) to reprogram cell phenotypes, or to provide enzymes such as RNA-guided Cas9 derivatives for CRISPR-based cell engineering.. While viral vector-mediated gene transfer has played an important role in this field, the use of mRNA avoids safety concerns associated with the integration of DNA into the host cell genome, making mRNA particularly attractive for in vivo applications.. Widespread application of mRNA for cell engineering is limited by its instability in the biological environment and challenges involved in the delivery of mRNA to its target site.

Article Title: Emerging mRNA Technology for Liver Disease Therapy.
Article Snippet: Liver diseases have consistently posed substantial challenges to global health.. It is crucial to find innovative methods to effectively prevent and treat these diseases.. In recent times, there has been an increasing interest in the use of mRNA formulations that accumulate in liver tissue for the treatment of hepatic diseases.

Article Title: Developing mRNA Nanomedicines with Advanced Targeting Functions.
Article Snippet: In 2024, Moderna reported the interim clinical results of mRNA-3927, which was delivered to the liver for the expression of propionyl-coenzyme A carboxylase α or β (PCCA or PCCB) subunits to participate in the conversion of propionic acid (Fig. 11e).

Article Title: Intranasal and Pulmonary Lipid Nanoparticles for Gene Delivery: Turning Challenges into Opportunities
Article Snippet: Beyond respiratory conditions, LNP-mRNA therapeutics are being evaluated for metabolic disorders, including Moderna’s mRNA-3704 for methylmalonic acidemia (Clinical Trial NCT03810690 ) and mRNA-3927 (Clinical Trial NCT04159103 ) for propionic acidemia.

Article Title: Developing mRNA Nanomedicines with Advanced Targeting Functions
Article Snippet: In 2024, Moderna reported the interim clinical results of mRNA-3927, which was delivered to the liver for the expression of propionyl-coenzyme A carboxylase α or β (PCCA or PCCB) subunits to participate in the conversion of propionic acid (Fig. e).

Virus:

Article Title: Nucleic acid therapeutics: Past, present, and future
Article Snippet: , NCT05130437 , Genetic (propionic acidemia) , LNP , mRNA-3927 (Moderna) , i.v.

Article Title: Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems
Article Snippet: The positive results of mRNA-3927 [ ] developed by Moderna in the clinical trial of treating propionic acidemia reduced the risk of life-threatening metabolic decompensation in patients by 70%, providing new hope for the treatment of rare genetic diseases and further demonstrating the broad prospects of mRNA therapy in the fields of precision medicine and rare disease treatment.

Article Title: Therapeutic applications of cell engineering using mRNA technology.
Article Snippet: Safety advantages are driving the rapid Engineering and reprogramming cells has significant therapeutic potential to treat a wide range of diseases, by replacing missing or defective proteins, to provide transcription factors (TFs) to reprogram cell phenotypes, or to provide enzymes such as RNA-guided Cas9 derivatives for CRISPR-based cell engineering.. While viral vector-mediated gene transfer has played an important role in this field, the use of mRNA avoids safety concerns associated with the integration of DNA into the host cell genome, making mRNA particularly attractive for in vivo applications.. Widespread application of mRNA for cell engineering is limited by its instability in the biological environment and challenges involved in the delivery of mRNA to its target site.

Article Title: Emerging mRNA Technology for Liver Disease Therapy.
Article Snippet: Liver diseases have consistently posed substantial challenges to global health.. It is crucial to find innovative methods to effectively prevent and treat these diseases.. In recent times, there has been an increasing interest in the use of mRNA formulations that accumulate in liver tissue for the treatment of hepatic diseases.

Article Title: Developing mRNA Nanomedicines with Advanced Targeting Functions.
Article Snippet: In 2024, Moderna reported the interim clinical results of mRNA-3927, which was delivered to the liver for the expression of propionyl-coenzyme A carboxylase α or β (PCCA or PCCB) subunits to participate in the conversion of propionic acid (Fig. 11e).

Article Title: Intranasal and Pulmonary Lipid Nanoparticles for Gene Delivery: Turning Challenges into Opportunities
Article Snippet: Beyond respiratory conditions, LNP-mRNA therapeutics are being evaluated for metabolic disorders, including Moderna’s mRNA-3704 for methylmalonic acidemia (Clinical Trial NCT03810690 ) and mRNA-3927 (Clinical Trial NCT04159103 ) for propionic acidemia.

Article Title: Developing mRNA Nanomedicines with Advanced Targeting Functions
Article Snippet: In 2024, Moderna reported the interim clinical results of mRNA-3927, which was delivered to the liver for the expression of propionyl-coenzyme A carboxylase α or β (PCCA or PCCB) subunits to participate in the conversion of propionic acid (Fig. e).

Vaccines:

Article Title: Nucleic acid therapeutics: Past, present, and future
Article Snippet: , NCT05130437 , Genetic (propionic acidemia) , LNP , mRNA-3927 (Moderna) , i.v.

Article Title: Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems
Article Snippet: The positive results of mRNA-3927 [ ] developed by Moderna in the clinical trial of treating propionic acidemia reduced the risk of life-threatening metabolic decompensation in patients by 70%, providing new hope for the treatment of rare genetic diseases and further demonstrating the broad prospects of mRNA therapy in the fields of precision medicine and rare disease treatment.

Article Title: Therapeutic applications of cell engineering using mRNA technology.
Article Snippet: Safety advantages are driving the rapid Engineering and reprogramming cells has significant therapeutic potential to treat a wide range of diseases, by replacing missing or defective proteins, to provide transcription factors (TFs) to reprogram cell phenotypes, or to provide enzymes such as RNA-guided Cas9 derivatives for CRISPR-based cell engineering.. While viral vector-mediated gene transfer has played an important role in this field, the use of mRNA avoids safety concerns associated with the integration of DNA into the host cell genome, making mRNA particularly attractive for in vivo applications.. Widespread application of mRNA for cell engineering is limited by its instability in the biological environment and challenges involved in the delivery of mRNA to its target site.

Article Title: Emerging mRNA Technology for Liver Disease Therapy.
Article Snippet: Liver diseases have consistently posed substantial challenges to global health.. It is crucial to find innovative methods to effectively prevent and treat these diseases.. In recent times, there has been an increasing interest in the use of mRNA formulations that accumulate in liver tissue for the treatment of hepatic diseases.

Article Title: Developing mRNA Nanomedicines with Advanced Targeting Functions.
Article Snippet: In 2024, Moderna reported the interim clinical results of mRNA-3927, which was delivered to the liver for the expression of propionyl-coenzyme A carboxylase α or β (PCCA or PCCB) subunits to participate in the conversion of propionic acid (Fig. 11e).

Article Title: Intranasal and Pulmonary Lipid Nanoparticles for Gene Delivery: Turning Challenges into Opportunities
Article Snippet: Beyond respiratory conditions, LNP-mRNA therapeutics are being evaluated for metabolic disorders, including Moderna’s mRNA-3704 for methylmalonic acidemia (Clinical Trial NCT03810690 ) and mRNA-3927 (Clinical Trial NCT04159103 ) for propionic acidemia.

Article Title: Developing mRNA Nanomedicines with Advanced Targeting Functions
Article Snippet: In 2024, Moderna reported the interim clinical results of mRNA-3927, which was delivered to the liver for the expression of propionyl-coenzyme A carboxylase α or β (PCCA or PCCB) subunits to participate in the conversion of propionic acid (Fig. e).



Similar Products

86
Moderna mrna 3927
Mrna 3927, supplied by Moderna, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna-3927/3927+mrna/pmc13011059-166-0-2
Average 86 stars, based on 1 article reviews
mrna 3927 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

86
Moderna moderna mrna 3927
Moderna Mrna 3927, supplied by Moderna, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna-3927/3927+mrna/pm41824151-174-10-10
Average 86 stars, based on 1 article reviews
moderna mrna 3927 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

90
Moderna mrna-3927
Mrna 3927, supplied by Moderna, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna-3927/mrna+3927/pmc12204099-51-22-12
Average 90 stars, based on 1 article reviews
mrna-3927 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results